Asset
Azenosertib
Zentalis Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07546500 | phase3 | recruiting | 2026-04-17 | 2028-05-31 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression |
| NCT05198804 | phase1_2 | completed | 2022-01-27 | 2025-10-15 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer |
| NCT04833582 | phase1 | completed | 2021-08-01 | 2023-08-30 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma |
| NCT04158336 | phase1 | completed | 2019-11-01 | 2025-05-06 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors |
| NCT04516447 | phase1 | recruiting | 2020-10-26 | 2028-06-30 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer |
FDA applications (0)
This company has no applications containing this asset.